# Retatrutide (LY3437943): Triple Receptor Design and What It Means for Study Design > Three receptor arms on one 39-residue backbone, in a fixed ratio no compound combination can copy. Also three reasons the data are harder to interpret. Web page: https://peptidemedixeu.com/en/learn/what-is-retatrutide/ · Peptide Medix EU · 5 min read · Updated: 2026-05-26 Three receptors respond to one molecule in the case of [retatrutide](https://peptidemedixeu.com/en/products/retatrutide/), a synthetic acylated 39-residue peptide and the [triple agonist](https://peptidemedixeu.com/en/glossary/triple-agonist/) examined most closely in metabolic science. Its distinguishing element is activity at the glucagon receptor, adding direct influence over whole-body energy use and liver substrate traffic that neither mono- nor dual-incretin molecules provide. Our research-grade retatrutide ships as sealed vials of lyophilized powder, intended exclusively for laboratory investigation. No regulator anywhere has authorised retatrutide as of 2026. The compound remains investigational, supported by published trial results, and what we supply is laboratory reference chemical rather than any kind of therapeutic article. ## A precise definition Papers refer to the compound as LY3437943. It sits in the proglucagon superfamily and was built so a single chain keeps worthwhile binding at a trio of kindred class B receptors. Their shared descent from ancestral genes leaves substantial homology between GIP, GLP-1 and glucagon, and that kinship permits overlapping pharmacophores, so one scaffold can be steered toward all of them. Creating such a molecule is accordingly not a question of stitching three drugs together but of hunting for substitutions that keep a trio of binding profiles in serviceable proportion at once. ## Structure and engineering - Scaffold: a GIP-related chain of 39 amino acids from the proglucagon superfamily, matching tirzepatide in length while bearing the residue changes that bring glucagon receptor binding back. - Aib residues: alpha-aminoisobutyric acid placed toward the N-terminal end deletes the site DPP-4 would cut and rigidifies the helix that seats itself in the receptor's extracellular region. - Lipidation: a C20 fatty diacid joined via gamma-glutamyl and ethoxy linkers confers the reversible albumin association and the lengthy circulating presence pharmacokinetic papers describe. - Published activity profile: high potency at GIPR, high potency at GLP-1R, and a lower but still pharmacologically relevant potency at GCGR. That asymmetry was chosen, not stumbled upon. For ordering: CAS 2381089-83-2, C221H342N46O68, 4731.30 Da. Since this value falls [not far from tirzepatide's](https://peptidemedixeu.com/en/learn/what-is-tirzepatide/), separating the two on a mass spectrum calls for sufficient instrument resolution plus a calculated value to check against, never a glance at the trace. ## Proposed mechanism Nothing unusual happens on the incretin side: like other [incretin agonists](https://peptidemedixeu.com/en/glossary/incretin/), both arms couple through Gs, build cAMP and boost insulin release from islets in a glucose-dependent fashion, while receptors in the brain and on vagal afferents are implicated in the rodent feeding changes. The glucagon component is what separates this molecule from the rest. Preclinical reports describe liver cells responding to glucagon receptor activation with higher cAMP, greater fat oxidation and increased whole-body energy use. Taken on its own that activation would also drive hepatic glucose release upward, an unhelpful outcome metabolically. Hence the reasoning behind these molecules: insulin secreted in a glucose-dependent manner under incretin signalling is expected to neutralise the glycaemic side of the glucagon effect while the expenditure side persists. Testing whether neutralisation survives across every concentration is exactly what laboratories use this compound for, and no answer is possible without arms designed to tease the three receptor contributions apart. There is a cost to the architecture, and it should be named. Every extra target squeezed onto one ligand narrows the chemistry in which all the affinities remain tolerable, leaving triple agonists generally less potent at any given receptor than a purpose-built agonist for it. Semaglutide outperforms this molecule as a [GLP-1 agonist](https://peptidemedixeu.com/en/glossary/glp-1/), and a selective GIP analogue outperforms it at GIPR. Its experimental value lies elsewhere, in concurrency: a trio of signals landing on one tissue together in an unvarying proportion, which mixtures of separate compounds cannot copy precisely because each clears at its own rate. ## Research to date - Work in cells: potency measured by cAMP at the human receptors in recombinant lines, together with binding experiments and beta-arrestin recruitment, all serving to fix the three-way ratio that characterises the compound. - Work in rodents: obesity produced by diet, with intake and fat mass tracked; calorimetry used to isolate the expenditure attributable to glucagon receptor signalling; and measurements of fat within the liver. Knockout animals and selective blockers allow effects to be traced to one arm or another. - Trials in people: phase 2 findings are in print, and by 2026 phase 3 programmes covering obesity and adjacent metabolic endpoints had reported, as summarised in our note on what the published retatrutide data actually showed. Those studies concern a supervised investigational medicine and say nothing applicable to laboratory powder. Interest concentrates on the liver, since glucagon receptor signalling reaches that tissue without an intermediary, giving this compound value as a probe wherever hepatic fat handling is under study and an incretin-only molecule would act only at one remove. Approach the literature with two caveats in mind. Ratios depend on the assay that produced them: cAMP potencies from a [recombinant overexpression](https://peptidemedixeu.com/en/glossary/recombinant/) line need not match what primary cells with natural receptor densities give, so figures lifted from different papers do not line up. Additionally, species differences are wider for the glucagon receptor than for incretin receptors, meaning a rodent finding attributed to that arm stays species-specific until someone repeats it at the human receptor. Adding an arm with a glucagon receptor blocker remains the tidiest way to establish whether that arm is responsible for an effect. ## Formats and sizes Vial sizes and current pricing appear on the retatrutide product page, together with the rest of the GLP-1 and incretin range. ## Reconstitution and storage in the lab What follows is a calculation, not a direction for use. Put 2 mL of [bacteriostatic water into](https://peptidemedixeu.com/en/products/bacteriostatic-water/) a 20 mg vial and the result is 10 mg/mL, equivalently 10,000 mcg/mL, which places 1,000 mcg of peptide in every 0.1 mL. Pour the diluent against the glass, allow the cake to go into solution without agitation, and verify clarity before continuing. Mechanical stress aggregates acylated peptides of this size easily, and no purity certificate issued before shipping can warn you about aggregation that happens on your bench. Unopened powder holds up at minus 20 degrees Celsius provided light and damp are excluded. Once in solution, keep it between 2 and 8 degrees Celsius and finish it inside the study period. Split it into portions the moment it dissolves, so that successive [freeze-thaw rounds](https://peptidemedixeu.com/en/glossary/freeze-thaw-cycle/) do not eat into a costly stock. Our reconstitution guide covers the mechanics in full. ## Purity and reading the COA Expect the certificate to carry a chromatogram with the main peak's area percentage, an MS identity figure compared with the calculated 4731.30 Da, the net peptide content, the lot number and the analysis date. Both this compound and tirzepatide are C20-acylated chains of 39 residues with masses lying close together, so [establishing which one you hold matters](https://peptidemedixeu.com/en/learn/mass-spectrometry-peptide-identity/) more than it would for a structurally unmistakable molecule, and no purity percentage answers that question. Consult the mass spectrometry identity note, and check the lot against the label every time. One more practical distinction separates this molecule from the rest of the incretin shelf. Since three arms fire together, a composite endpoint rarely traces a clean sigmoid against concentration: whichever receptor dominates changes as occupancy rises, and forcing a single-mechanism fit onto such data returns a potency number that corresponds to nothing real. Interpretable results need wide ranges sampled at many points rather than the three or four a single-receptor study would use, which in turn determines how much material an experiment gets through. ## Regulatory position Through 2026 the compound carries no authorisation in the EU, the United States or elsewhere. Its status is investigational: examined in registered trials under regulatory oversight, not dispensed as a prescription product. We sell it as a laboratory reference chemical, and encouraging trial results open no route to human use for material of that grade. ## Related compounds and comparisons Natural points of reference are tirzepatide, which hits two receptors, and semaglutide, which hits one; see retatrutide vs tirzepatide and semaglutide vs retatrutide. Where a second glucagon-receptor-containing molecule is wanted for contrast, survodutide fits. ## Frequently asked questions ### Why is retatrutide called a triple agonist? One chain of 39 amino acids holds workable binding at a trio of kindred class B receptors, those for GIP, GLP-1 and glucagon. Common ancestry and homology between them let a single engineered scaffold reach all three. The potencies are unequal, and that asymmetry was designed in rather than being a defect. ### What is the reason for adding glucagon receptor activity? Studies before the clinic report that activating this receptor lifts fat oxidation in the liver and raises whole-body energy use. Unaccompanied it would also increase glucose release from the liver, so the rationale is that glucose-dependent incretin signalling running at the same time cancels that while leaving the expenditure benefit intact. Nobody has yet established whether the cancellation survives at every concentration. ### Has retatrutide been approved as a medicine? No. Nowhere in the world had authorised it by 2026. The molecule stays investigational, appearing in registered trials whose phase 2 and phase 3 findings have been published. ### How does its structure compare with tirzepatide's? Each is an acylated chain of 39 residues from the proglucagon superfamily, weighing 4731.30 Da and 4813.45 Da respectively. What differs are the residue changes conferring glucagon receptor binding, present in one and absent in the other. Because the masses sit so near each other, identity confirmation by MS is important whichever of the two you buy. ### Which vial sizes exist? Sealed lyophilized vials at 10 mg, 20 mg, 30 mg, 48 mg and 60 mg, every one accompanied by its own certificate. The bigger formats fit animal studies with several arms, where sourcing all conditions from a single lot eliminates batch variation as a confounder, while the smaller ones fit receptor and cell experiments. ### What are the storage requirements? Unopened powder belongs at minus 20 degrees Celsius with light and damp excluded, while dissolved material sits between 2 and 8 degrees Celsius in the dark and is finished inside the study period. Divide it into portions immediately once dissolved, so that thawing and refreezing does not spoil what is left. ### Can one experiment attribute an effect to a single receptor? Rarely, no. With the three arms firing together, a useful design needs mono-receptor comparators, selective blockers or animals lacking a receptor. Lacking those, whatever the compound produces can be reported but cannot be pinned on signalling through any one of the three. ## Related products - [Retatrutide](https://peptidemedixeu.com/en/products/retatrutide/): from €63 --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.